We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
21.7
quarters
Top 10 Avg Time Held
6.6
quarters
Top 20 Avg Time Held
9.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1776
AN2 Therapeutics
ANTX
$160M
| $13K | ﹤0.01% |
12,237
| – | – |
2023 Q3
7 quarters
|
|
1777
DELISTED
iRobot
IRBT
| $12.9K | ﹤0.01% |
4,136
-716,261
| -99% | -$1.98M |
2024 Q1
5 quarters
|
|
1778
Nuvation Bio
NUVB
$1.72B
| $12.9K | ﹤0.01% |
6,610
-3,946
| -37% | -$8.22K |
2023 Q2
8 quarters
|
|
1779
Ladder Capital
LADR
$1.11B
| $12.9K | ﹤0.01% |
1,198
| – | – |
2023 Q3
7 quarters
|
|
1780
Eagle Bancorp
EGBN
$878M
| $12.8K | ﹤0.01% |
+657
| New | +$12.2K |
2025 Q2
0 quarters
|
|
1781
Cardlytics
CDLX
$13.1M
| $12.8K | ﹤0.01% |
778
+316
| +68% | +$5.46K |
2025 Q1
1 quarter
|
|
1782
Erasca
ERAS
$5.44B
| $12.8K | ﹤0.01% |
10,070
-4,920
| -33% | -$6.59K |
2024 Q2
4 quarters
|
|
1783
Colony Bankcorp
CBAN
$426M
| $12.7K | ﹤0.01% |
+770
| New | +$11.9K |
2025 Q2
0 quarters
|
|
1784
Unity
U
$20.6B
| $12.7K | ﹤0.01% |
523
-3,968
| -88% | -$87.3K |
2024 Q3
3 quarters
|
|
1785
Green Brick Partners
GRBK
$2.68B
| $12.6K | ﹤0.01% |
200
-93
| -32% | -$5.51K |
2020 Q2
20 quarters
|
|
1786
Northeast Community Bancorp
NECB
$379M
| $12.5K | ﹤0.01% |
536
| – | – |
2023 Q4
6 quarters
|
|
1787
Atea Pharmaceuticals
AVIR
$411M
| $12.4K | ﹤0.01% |
3,442
-579,287
| -99% | -$1.73M |
2022 Q1
13 quarters
|
|
1788
Matsons
MATX
$6.84B
| $12.4K | ﹤0.01% |
111
+33
| +42% | +$3.61K |
2025 Q1
1 quarter
|
|
1789
HSBC
HSBC
$324B
| $12.3K | ﹤0.01% |
203
| – | – |
2021 Q2
16 quarters
|
|
1790
Seagate
STX
$172B
| $12.3K | ﹤0.01% |
+85
| New | +$8.8K |
2025 Q2
0 quarters
|
|
1791
Progyny
PGNY
$2.14B
| $12.2K | ﹤0.01% |
556
-254
| -31% | -$5.57K |
2019 Q4
22 quarters
|
|
1792
DELISTED
First Savings Financial Group
FSFG
| $12.2K | ﹤0.01% |
+488
| New | +$12.5K |
2025 Q2
0 quarters
|
|
1793
Vita Coco
COCO
$3.32B
| $12.2K | ﹤0.01% |
338
+111
| +49% | +$3.71K |
2023 Q1
9 quarters
|
|
1794
United Parks & Resorts
PRKS
$1.55B
| $12.1K | ﹤0.01% |
257
-121
| -32% | -$5.4K |
2021 Q1
17 quarters
|
|
1795
Replimune Group
REPL
$1.27B
| $12K | ﹤0.01% |
1,291
-423
| -25% | -$3.69K |
2024 Q3
3 quarters
|
|
1796
SI-BONE Inc
SIBN
$875M
| $12K | ﹤0.01% |
+635
| New | +$10.5K |
2025 Q2
0 quarters
|
|
1797
Universal Electronics
UEIC
$70.9M
| $11.9K | ﹤0.01% |
1,792
+817
| +84% | +$4.99K |
2023 Q1
9 quarters
|
|
1798
Tecnoglass Holdings
TGLS
$1.67B
| $11.8K | ﹤0.01% |
153
+82
| +115% | +$6.36K |
2024 Q4
2 quarters
|
|
1799
Forum Energy Technologies
FET
$999M
| $11.8K | ﹤0.01% |
606
+488
| +414% | +$7.9K |
2025 Q1
1 quarter
|
|
1800
Enovis
ENOV
$1.05B
| $11.8K | ﹤0.01% |
376
-50
| -12% | -$1.65K |
2015 Q4
38 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.